Latest News

  • 22nd March 2023

    FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278

  • 16th February 2023

    ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY FORMULATIONS

  • 14th February 2023

    ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT

News

Reset
  • 22/03/2023

    FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278

  • 16/02/2023

    ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY FORMULATIONS

  • 14/02/2023

    ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT

  • 30/01/2023

    ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT278 IN DIABETES CARE

  • 12/01/2023

    ARECOR ANNOUNCES TRANSFER OF AT307 TO HIKMA